Visionary Holdings Announces Continued Progress of Approximately US$9 Million Sales Contract
Rhea-AI Summary
Visionary Holdings (NASDAQ: GV) said its subsidiary GV Hong Kong is executing a previously signed commercial sales agreement with a total contract value of approximately US$9 million (signed September 2025).
Early-stage service activities are underway and the company expects further substantive execution milestones by the end of the first quarter of 2026, with revenue recognition and cash collection following contractual terms and applicable accounting standards.
Positive
- US$9 million commercial contract signed September 2025
- Phased implementation and early-stage service activities underway
- Company expects substantive milestones by end Q1 2026
Negative
- Revenue not yet recognized; recognition tied to future milestones
- Cash collection pending and subject to contract timing and accounting
Key Figures
Market Reality Check
Peers on Argus
GV fell 3.77% while peers showed mixed moves: WAFU up 4.32%, AMBO, EEIQ, FEDU and KIDZ down between 5–12%. With no peers in the momentum scanner and no same-day peer headlines, today’s move appears more company-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | China expansion | Positive | -1.8% | New wholly owned subsidiaries to support regenerative medicine commercialization in China. |
| Feb 13 | Debt financing | Neutral | +0.9% | Senior secured convertible promissory note providing <b>$450,000</b> in gross proceeds. |
| Feb 04 | Nasdaq compliance | Positive | -2.5% | Nasdaq closed a listing deficiency after the Form 20-F filing confirmed compliance. |
| Feb 02 | Filing compliance | Positive | +0.0% | Regained compliance with Nasdaq periodic filing rules via timely Form 20-F submission. |
| Jan 20 | Annual results | Negative | +2.5% | FY2025 revenue decline, significant net loss and negative working capital disclosure. |
Recent GV news has produced small, mixed price reactions, with several ostensibly positive items (Nasdaq compliance, China expansion) followed by flat or negative moves, and even negative financials coinciding with a positive reaction.
Over the last few months, GV has reported a strategic pivot toward high-end health and anti-aging, alongside weak legacy businesses. On Jan 20, FY2025 revenue was $5.04M with a $15.75M net loss and large negative working capital, yet shares rose 2.46%. Subsequent filings on Jan 28 confirmed Nasdaq compliance. In February, debt financing and new Chinese subsidiaries were announced, but price reactions were modest to negative. Today’s execution update on a ~$9M contract fits the ongoing health-focus narrative.
Market Pulse Summary
This announcement highlights continued execution on a commercial agreement with a total value of approximately US$9M, tied to high-end health management and VIP medical services. It reinforces GV’s strategic shift toward health and anti-aging businesses, following FY2025 results that showed $5.04M revenue and a $15.75M net loss with sizable negative working capital. Investors may focus on how and when milestones convert into recognized revenue and cash, and how this contract scales relative to the broader life-sciences roadmap.
Key Terms
revenue recognition financial
forward-looking statements regulatory
AI-generated analysis. Not financial advice.
Expects Significant Milestone Advancement by the End of March 2026
HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US
The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway. GV Hong Kong is working closely with its business partner to advance phased implementation efforts under the terms of the agreement.
Execution Update
Since the signing of the agreement, both parties have continued to advance contractual milestones. Early-stage service activities remain in progress. Based on the current delivery schedule and client coordination progress, the Company expects the agreement to achieve further substantive execution milestones by the end of the first quarter of 2026.
Any related revenue recognition and cash collection will be recorded in accordance with the terms of the agreement and applicable accounting standards.
Product and Service Overview
The commercial scope of the agreement includes:
The Premier Regenerative Complex product series, positioned within high-end health management solutions; Customized VIP health services centered on individualized medical evaluations and physician-guided programs. These services are delivered within a structured medical oversight framework and are tailored based on individual health assessments.
Management Commentary
Mr. Hou Xiyong, Chief Executive Officer of Visionary Holdings, commented:
“The continued execution of this agreement reflects our ability to effectively convert strategic partnerships into operational results. We remain committed to disciplined delivery, compliance-driven revenue recognition, and long-term value creation. As performance progresses, we believe this business segment has the potential to contribute positively to our revenue growth and margin profile.”
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Contacts:
Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings
FAQ
What is the size and timing of Visionary Holdings' (GV) sales contract announced February 24, 2026?
When does Visionary Holdings (GV) expect to achieve milestones and recognize revenue from the US$9 million contract?
What products and services are included in GV's US$9 million commercial agreement (GV)?
Has Visionary Holdings (GV) started delivering services under the September 2025 contract?
Will the US$9 million contract immediately affect Visionary Holdings' (GV) reported revenue?
What operational risks should investors consider about Visionary Holdings' (GV) contract execution?
